logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Retinoid class drugs

    FiltersReset Filters
    13 results

    • accutane

      (ISOTRETINOIN)
      JG Pharma Inc.
      Usage: Accutane is indicated for severe recalcitrant nodular acne in patients unresponsive to conventional therapy, including systemic antibiotics. It is contraindicated in pregnant patients due to potential life-threatening birth defects. A single 15 to 20-week treatment course may lead to prolonged remission.

    • aklief

      (trifarotene)
      Galderma Laboratories, L.P.
      Usage: AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients aged 9 years and older.

    • altreno

      (tretinoin)
      Bausch Health US, LLC
      Usage: ALTRENO® (tretinoin) lotion, 0.05% is indicated for the topical treatment of acne vulgaris in patients aged 9 years and older.

    • arazlo

      (tazarotene)
      Bausch Health US, LLC
      Usage: ARAZLO® (tazarotene) lotion, 0.045% is indicated for the topical treatment of acne vulgaris in patients aged 9 and older.

    • duobrii

      (halobetasol propionate and tazarotene)
      Bausch Health US, LLC
      Usage: DUOBRII® (halobetasol propionate and tazarotene) Lotion is indicated for the topical treatment of plaque psoriasis in adults.

    • epiduo

      (adapalene and benzoyl peroxide)
      Galderma Laboratories, L.P.
      Usage: EPIDUO gel is indicated for the topical treatment of acne vulgaris in patients aged 9 years and older.

    • fabior

      (tazarotene)
      Mayne Pharma
      Usage: FABIOR® (tazarotene) Foam, 0.1% is indicated for the topical treatment of acne vulgaris in patients aged 12 years and older.

    • retin-a micro

      (Tretinoin)
      Bausch Health US LLC
      Usage: Retin-A Micro® is a retinoid indicated for topical use in the treatment of acne vulgaris.

    • sohonos

      (palovarotene)
      Ipsen Biopharmaceuticals, Inc.
      Usage: SOHONOS is indicated for reducing the volume of new heterotopic ossification in adults and pediatric patients with fibrodysplasia ossificans progressiva (FOP), specifically in females aged 8 years and older and males aged 10 years and older.

    • targretin

      (bexarotene)
      Bausch Health US, LLC
      Usage: Targretin (bexarotene) gel 1% is indicated for the topical treatment of cutaneous lesions in patients with Stage IA and IB CTCL, specifically for those with refractory or persistent disease or who have not tolerated other therapies.